Evidence map›Paper›PMID 30807924›Full record

ReviewDNA repair2019

USP7: Structure, substrate specificity, and inhibition.

Alexandra Pozhidaeva, Irina Bezsonova

Open access · greenAbstract readReview
In one paragraph

Review in DNA repair, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 164 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. USP7 at PML Nuclear Bodies: A Protein Interaction Network Perspective.International journal of molecular sciences · 2026
    Article
  11. Article
  12. Article
  13. Ubiquitin System-Driven Proteostasis in DNA Damage Response.International journal of molecular sciences · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Alexandra PozhidaevaDepartment of Molecular Biology and Biophysics, UCONN Health, Farmington, CT, USA; Department of Biochemistry and Molecular Biology, University of Massachusetts, Amherst, MA, USA.
Irina BezsonovaDepartment of Molecular Biology and Biophysics, UCONN Health, Farmington, CT, USA. Electronic address: bezsonova@uchc.edu.
UConn Health · USUniversity of Massachusetts Amherst · US

Funding

UBIQUITIN-PROTEASOME PATHWAY IN CANCERR35GM128864 · NIGMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI BEZSONOVA, IRINA · 2018 to 2022
$1.6M
NIGMS NIH HHS R35 GM128864
6 · The paper itself

Abstract

Turnover of cellular proteins is regulated by Ubiquitin Proteasome System (UPS). Components of this pathway, including the proteasome, ubiquitinating enzymes and deubiquitinating enzymes, are highly specialized and tightly regulated. In this mini-review we focus on the de-ubiquitinating enzyme USP7, and summarize latest advances in understanding its structure, substrate specificity and relevance to human cancers. There is increasing interest in UPS components as targets for cancer therapy and here we also overview the recent progress in the development of small molecule inhibitors that target USP7.

Indexed as

AnimalsEnzyme InhibitorsHumansSubstrate SpecificityUbiquitin-Specific Peptidase 7Enzyme InhibitorsUbiquitin-Specific Peptidase 7CancerDeubiquitinating enzymeDUB inhibitionUbiquitin-proteasome pathwayUSP7

Identifiers

PMID30807924
PMCPMC6481172
OpenAlexW2914005285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.